EGFR-inhibiting agents such as EGFR-blocking antibodies or EGFR tyrosine kinase inhibitors have been approved to treat various cancers, including colorectal and non-small cell lung cancers.26 Here, EGFR is linked to non-small cell lung carcinoma.